Table 4.
Treatments and outcomes of COVID-19 patients.
| Treatments and outcomes | All patients | Disease severity | P value | ||
|---|---|---|---|---|---|
| Common | Severe | Critical | |||
| Number | 95 | 54 (56.8) | 27 (28.4) | 14 (14.7) | NA |
| Treatment | |||||
| HFNC | 13 (13.7) | 0 (0) | 6 (22.2) | 7 (50.0) | ＜0.001 |
| NIV | 12 (12.6) | 0 (0) | 5 (18.5) | 7 (50.0) | ＜0.001 |
| IV | 5 (5.3) | 0 (0) | 0 (0) | 5 (35.7) | ＜0.001 |
| Antiviral therapy | 91 (95.8) | 52 (96.3) | 25 (92.6) | 14 (100.0) | 0.513 |
| Abidol | 41 (43.2) | 20 (37.0) | 14 (51.9) | 7 (50.0) | 0.382 |
| Oseltamivir | 31 (32.6) | 18 (33.3) | 7 (25.9) | 6 (42.9) | 0.541 |
| Ganciclovir | 33 (34.7) | 17 (31.5) | 10 (37.0) | 6 (42.9) | 0.697 |
| Lopinavir plus ritonavir | 55 (57.9) | 32 (59.3) | 15 (55.6) | 8 (57.1) | 0.949 |
| Ribavirin | 24 (25.3) | 12 (22.2) | 7 (25.9) | 5 (35.7) | 0.583 |
| Interferon | 14 (14.7) | 5 (9.3) | 5 (18.5) | 4 (28.6) | 0.155 |
| Moxifloxacin∗ | 85 (89.5) | 47 (87.0) | 24 (88.9) | 14 (100) | 0.368 |
| Levofloxacin | 14 (14.7) | 6 (11.1) | 6 (22.2) | 2 (14.3) | 0.412 |
| Linezolid | 5 (5.3) | 1 (1.9) | 1 (3.7) | 3 (21.4) | 0.013 |
| Piperacillin | 20 (21.1) | 8 (14.8) | 10 (37.0) | 2 (14.3) | 0.055 |
| Meropenem | 6 (6.3) | 0 (0) | 4 (14.8) | 2 (14.3) | 0.015 |
| Fluconazole | 3 (3.2) | 0 (0) | 1 (3.7) | 2 (14.3) | 0.024 |
| Glucocorticoids | 32 (33.7) | 11 (20.4) | 12 (44.4) | 9 (64.3) | 0.003 |
| Immunoglobulin | 19 (20.0) | 12 (22.2) | 4 (14.8) | 3 (21.4) | 0.727 |
| ICU admission | 18 (18.9) | 2 (3.7) | 7 (25.9) | 9 (64.3) | ＜0.001 |
| Days from hospital admission to ICU | 6 (2–10) | NA | 4 (1–8) | 7.0 (3.0–11.5) | 0.272 |
| Outcome | |||||
| Died | 10 (10.5) | 0 (0) | 0 (0) | 10 (71.4) | ＜0.001 |
| Improved and discharged | 85 (89.5) | 54 (100.0) | 27 (100) | 4 (28.6) | ＜0.001 |
| Days from hospitalization to discharge | 19 (14.0–29.5) | 16.5 (13.0–21.8） | 28 (18–41) | NA | ＜0.001 |
| Days from hospitalization to death | 18 (11–25) | NA | NA | 18 (11–25) | NA |
Data are presented as n (%) or medians (interquartile ranges, IQR). NA: not appropriate; HFNC, high-flow nasal cannula oxygen therapy; NIV, noninvasive ventilation; IV, invasive ventilation. ∗The usage of moxifloxacin in this table is the data of COVID-19 patients before admission.